Skip to main content

Table 1 Clinical and biochemical characteristics of participants enrolled in the study

From: Stereotactic body radiation therapy as an effective and safe treatment for small hepatocellular carcinoma

Variables n (%)
Sex
 Male 21 (75.0)
 Female 7 (25.0)
Age (years)
 <60 20 (71.4)
 ≥60 8 (28.6)
Type of chronic hepatitis
 Hepatitis B 24 (85.7)
 Hepatitis C 4 (14.3)
Cirrhosis
 Yes 26 (92.9)
 No 2 (7.1)
AFP(ng/ml)
 <200 22 (78.6)
 ≥200 6 (21.4)
Child-Pugh classification
 A 24 (85.7)
 B 4 (14.3)
ECOG Score
 0 25 (89.3)
 1 3 (10.7)
Tumor diameter (cm)
 ≤2 cm 14 (50.0)
 >2 cm,≤3 cm 14 (50.0)
Use of fiducials in SBRT
 Yes 27 (96.4)
 No 1 (3.6)
Previous treatments
 No 10 (35.7)
 Resection 2 (7.1)
 TACE 13 (46.4)
 Resection+TACE 1 (3.6)
 TACE+RFA 1 (3.6)
 TACE+PCA 1 (3.6)
  1. NOTE. Data presented as No (%)
  2. Abbreviations: AFP alpha-fetoprotein, SBRT stereotactic body radiation therapy, TACE transarterial chemoembolization, RFA radiofrequency ablation, PCA percutaneous cryoablation
\